WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001032625) ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/032625    International Application No.:    PCT/US2000/030329
Publication Date: 10.05.2001 International Filing Date: 03.11.2000
Chapter 2 Demand Filed:    21.05.2001    
IPC:
C07D 217/04 (2006.01), C07D 401/04 (2006.01), C07D 405/04 (2006.01), C07D 409/04 (2006.01), C07D 413/04 (2006.01)
Applicants: DU PONT PHARMACEUTICALS COMPANY [US/US]; Chestnut Run Plaza, 974 Centre Road, Wilmington, DE 19805 (US)
Inventors: BECK, James, P.; (US).
CURRY, Matt, A.; (US).
SMITH, Mark, A.; (US)
Agent: FUZAIL, Kalim; Du Pont Pharmaceuticals Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US)
Priority Data:
60/163,269 03.11.1999 US
Title (EN) ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN
(FR) TETRAHYDROISOQUINOLINES A SUBSTITUTION ARYLE ET HETEROARYLE ET UTILISATION DE CES COMPOSES POUR BLOQUER LE RECAPTAGE DE NOREPINEPHRINE, DE DOPAMINE ET DE SEROTONINE
Abstract: front page image
(EN)Provided herein are compounds of formula (I), wherein R1-R8 are as described herein, R4 being aryl or heteroaryl. Such compounds are particularly useful in the treatment of a disorder which is created by or is dependent upon decreased availability of serotonin, norepinephrine or dopamine.
(FR)L'invention concerne des composés de la formule (I) dans laquelle R1-R8 ont la signification donnée dans le descriptif, R4 étant de l'aryle, ou de l'hétéroaryle. De tels composés sont particulièrement utiles dans le traitement d'un dysfonctionnement provoqué par ou dépandant d'une diminution de la disponibilité de sérotonine, de norepinéphrine, ou de dopamine.
Designated States: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA.
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).
Publication Language: English (EN)
Filing Language: English (EN)